Influence of erythropoiesis-stimulating agents on glycated hemoglobin in nondiabetic kidney diseases at the start of dialysis

American Journal of Nephrology

Volumn 33, Issue 1, 2011, Pages 17-24

  Cordeiro, Antonio Carlos ^a,c   Carrero, Juan Jesús ^a,b   Bárány, Peter ^b   Qureshi, Abdul Rashid ^a   Heimbürger, Olof ^b   Lindholm, Bengt ^a   Stenvinkel, Peter ^b,d  

^a Divisions of Baxter Novum and Renal Medicine   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic kidney disease; Erythropoiesis stimulating agents; Glycated hemoglobin

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TRIACYLGLYCEROL;

ADULT; ANEMIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CHOLESTEROL, HDL; COHORT STUDIES; DIABETES MELLITUS; FEMALE; GLUCOSE; HEMATINICS; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; KIDNEY; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 78649511090     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322608     Document Type: Article

References (39)

1. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521.
2. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49:S12-S154.
3. Levitan EB, Song Y, Ford ES, Liu S: Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004; 164: 2147-2155.
4. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE: Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AUSDIAB). Circulation 2007; 116: 151-157.
5. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW: Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005; 165: 1910-1916. (Pubitemid 41352087)
6. Lin-Tan DT, Lin JL, Wang LH, Wang LM, Huang LM, Liu L, Huang JY, Huang YL: Fasting glucose levels in predicting 1-year allcause mortality in patients who do not have diabetes and are on maintenance hemodialysis. J Am Soc Nephrol 2007; 18: 2385-2391.
7. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
9. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl 1):S62-S69.
10. Bunn HF, Gabbay KH, Gallop PM: The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978; 200: 21-27.
11. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362: 800-811.
12. Giugliano D, Ceriello A, Esposito K: Glucose metabolism and hyperglycemia. Am J Clin Nutr 2008; 87: 217S-222S.
13. Drechsler C, Krane V, Ritz E, Marz W, Wanner C: Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 2009; 120: 2421-2428.
14. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CJ, Whellan D, Sharma K: A1c and survival in maintenance hemodialysis patients. Diabetes Care 2007; 30: 1049-1055.
15. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, Ishimura E, Nishizawa Y: Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001; 24: 909-913.
16. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, Shoji T, Nishizawa Y: Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29: 1496-1500.
17. Yu CC, Wu MS, Wu CH, Yang CW, Huang JY, Hong JJ, Fan Chiang CY, Leu ML, Huang CC: Predialysis glycemic control is an independent predictor of clinical outcome in type II diabetics on continuous ambulatory peritoneal dialysis. Perit Dial Int 1997; 17: 262-268.
18. Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, Calles-Escandon J, Russell GB, Freedman BI: Comparison of glycated albumin and hemoglobin a(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008; 73: 1062-1068.
19. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y: Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903.
20. Freedman BI, Shihabi ZK, Andries L, Cardona CY, Peacock TP, Byers JR, Russell GB, Stratta RJ, Bleyer AJ: Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol 2010; 31: 375-379.
21. Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, Selvin E: The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes 2010; 59: 2020-2026.
22. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911.
23. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
25. Okada T, Nakao T, Yamanaka T, Tamekuni T, Ikeda: Influence of darbepoetin-alpha therapy on HbA(1c) values in hemodialysis patients. Clin Nephrol 2009; 72: 244-246.
26. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of hemoglobin a1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
27. Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM: Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006; 70: 1503-1509.
28. Blake GJ, Pradhan AD, Manson JE, Williams GR, Buring J, Ridker PM, Glynn RJ: Hemoglobin a1c level and future cardiovascular events among women. Arch Intern Med 2004; 164: 757-761.
29. Shurraw S, Majumdar SR, Thadhani R, Wiebe N, Tonelli M: Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis 2010; 55: 10.
30. Kovesdy CP, Park JC, Kalantar-Zadeh K: Glycemic control and burnt-out diabetes in esrd. Semin Dial 2010; 23: 148-156.
31. Kalantar-Zadeh K, Derose SF, Nicholas S, Benner D, Sharma K, Kovesdy CP: Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr 2009; 19: 33-37.
32. Brown JN, Kemp DW, Brice KR: Class effect of erythropoietin therapy on hemoglobin a(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis. Pharmacotherapy 2009; 29: 468-472.
33. Fitzgibbons JF, Koler RD, Jones RT: Red cell age-related changes of hemoglobins AIa+b and AIc in normal and diabetic subjects. J Clin Invest 1976; 58: 820-824.
34. Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M, Shino T, Yamada C, Nagaoka Y: Influence of erythropoietin treatment on hemoglobin a1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998; 37: 826-830.
35. Alfrey CP, Fishbane S: Implications of neocytolysis for optimal management of anaemia in chronic kidney disease. Nephron Clin Pract 2007; 106:c149-c156.
36. Frühbeck G, Salvador J: Relation between leptin and the regulation of glucose metabolism. Diabetologia 2000; 43: 3-12.
37. Müller S, Martin S, Koenig W, Hanifi- Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H: Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002; 45: 805-812.
38. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE: Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the diabetes control and complications trial. Diabetes Care 2002; 25: 275-278.
39. Moriyama K, Kanamoto N, Hataya Y, Nanbu T, Hosoda K, Arai H, Nakao K: A case of type 2 diabetes mellitus developing hypothyroidism discovered as a result of a discrepancy between glycated hemoglobin and glycated albumin values. Diabetes Res Clin Pract 2006; 71: 227-232.